Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries

Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied population at high risk for MDR pathogens. The primary objective of this study is to evaluate the pharmacokinetic principles of cefiderocol in patients after acute burn injury. Findings from this study will determine the dose and interval necessary to maintain therapeutic concentrations of cefiderocol in patients after burn injury for adequate bactericidal activity, prevention of resistance, and treatment outcomes.

NCT Number	NCT07465432
Lead Sponsor	University of Tennessee Collaborators: Shionogi Inc., Regional Medical Center, Regional One Health, Center for Anti-Infective Research and Development
Conditions	Drug Clearance After Severe Burn Injury
Enrollment	12 participants
Start Date	2026-02-16
Primary Completion	2027-02-28 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-03-12